There is no doubt that transformative therapies have attracted the attention of everyone, particularly investors, since they first started to gain regulatory approval. The excitement for the prospects of those new therapies has certainly influenced the share prices of companies using next-generation technologies. Read More
The quest to get the first drug approved to treat fragile X is heating up with three companies – Tetra Discovery Partners Inc., Zynerba Pharmaceuticals Inc. and Ovid Therapeutics Inc. – starting clinical trials this month. Read More
